51 results about "Dosing drugs" patented technology

Provided herein is the use of certain biomarkers, such as tryptophan and metabolites thereof for use in certain treatment methods. Suitable tryptophan metabolites that may serve as useful biomarkers include, for example, kynurenine (Kyn), kynurenic acid (KynA), and quinolinic acid. Such biomarkers may be used in identifying a subject who may benefit from treatment, predicting the responsiveness or monitoring the response of the subject to the treatment, or determining or adjusting the dosing or dosing regimen of the treatment to the subject.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

A clinical combination therapy comprising one or more pharmaceutical compositions for treating various cancers. The one or more pharmaceutical compositions include at least a first composition of an immune checkpoint inhibitor and a second composition that interacts with an extracellular matrix component of the tumor microenvironment. The first composition may, for example, include pembrolizumab, and the second composition may include an LAIR-2Fc fusion protein, such as NC410. The compositions follow a dosing and timing regimen.

This invention discloses a wearable ultrasound delivery device for treating otitis media, comprising a wearable main body with a flexible structure adapted to the shape of the patient's ear canal, and a through-hole central channel; an ultrasound drug delivery device, detachably disposed within the central channel, comprising a drug carrier for carrying the therapeutic drug to be delivered, an ultrasound transducer assembly for providing an ultrasound-guided drug delivery mode, and a handheld controller for adjusting the millimeter-level displacement of the drug carrier into the middle ear cavity; wherein, the ultrasound transducer assembly comprises a flexible substrate and multiple piezoelectric transducer units integrated on the flexible substrate, the multiple piezoelectric transducer units constituting a phased array transducer array. This device solves the technical problems of inaccurate drug delivery, low drug delivery efficiency, inability to adapt to the ear canal structure, and complex operation in the prior art.

Ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast formulated with optimized viscosity and are suitable for intravitreal or other forms of ocular administration. The compositions can improve drug administration and absorption, distribution, metabolism, and excretion (ADME) properties. The ophthalmic pharmaceutical formulations can be administered via intravitreal injection resulting in the formation of a depot in the vitreous. The depot can remain in the vitreous for a prolonged period of time resulting in therapeutic drug levels over this period of time and improved durability.

The utility model relates to the technical field of gynecological drug delivery structures, and discloses a gynecological drug delivery structure which comprises a drug delivery component and a drug delivery tube arranged at the front end of the drug delivery component, a vaginal dilation component is arranged on one side of the drug delivery component, a heating component is arranged on the outer side of the drug delivery component, a rotating rod is rotated, a pressing plate can be pushed to move, and a sponge body can be extruded. According to the vaginal dilation device, the movable vaginal dilation plate and the fixed vaginal dilation plate are provided with the discharge holes, so that the lubricating liquid is discharged from the discharge holes, the surface of the movable vaginal dilation plate and the surface of the fixed vaginal dilation plate are provided with the lubricating liquid respectively, the lubricating purpose can be achieved, and the discomfort caused when the movable vaginal dilation plate and the fixed vaginal dilation plate are inserted into the private part of a patient can be reduced; the threaded rod can be driven to rotate, the movable vaginal dilation plate can be driven by the sliding base to move, the movable vaginal dilation plate can be far away from the fixed vaginal dilation plate, the private part of a patient can be dilated, the push rod can push the piston to move by pressing the handle, and liquid medicine can be discharged from the medicine feeding pipe.

Provided is use of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) in the manufacture of a medicament for treating and / or preventing an immune system disease.

The utility model discloses an anorectal dosing device, and belongs to the technical field of medical instruments. An anorectum drug delivery device comprises a drug delivery device body, the drug delivery device body comprises a drug storage tube, a drug storage cavity is formed in the drug storage tube, a drug delivery tube communicated with the drug storage cavity is formed at one end of the drug storage tube, the drug delivery tube is used for stretching into the anorectum of a patient, an air bag is formed at the drug delivery tube, and a driving piece penetrating through the other end of the drug storage tube is slidably arranged in the drug storage tube. A through hole communicated with the medicine storage cavity is formed in the driving piece, a connecting pipe is arranged in the through hole, one end of the connecting pipe penetrates through the medicine storage cavity to be communicated with the air bag, and the other end of the connecting pipe is connected with the inflation assembly. Through the arrangement of the air bag, the effect of fixing the dosing tube is achieved, the dosing tube is prevented from sliding or shifting in the dosing process, a certain sealing effect can be achieved on the anorectum of a patient through the expansion effect, loss of liquid medicine in the dosing process is reduced, it is ensured that medicine can make full contact with the affected part, the dosing effect is improved, and then the treatment effect is improved.

The invention relates to a preparation method and application of a hydrogel microneedle loaded with a glutathione storage cavery.The preparation method aims at achieving more efficient drug delivery, and according to the technical scheme, the preparation method specifically comprises the following steps that 1, a PDMS microneedle female template is prepared; 2) preparing a hydrogel microneedle material solution; 3) preparing a blank hydrogel microneedle; (4) preparing a hydrogel microneedle loaded with a glutathione storage cavern; the hydrogel microneedle loaded with the glutathione reservoir integrates the advantages of the hydrogel microneedle and the drug reservoir, the hydrogel microneedle can form a tiny channel on the skin surface, percutaneous delivery of drugs is promoted, the drug delivery efficiency is improved, the drug reservoir is carried, and the drug delivery efficiency is improved. The hydrogel microneedle has the advantages that glutathione can be prevented from being degraded due to high-temperature crosslinking and the like in the preparation process of the microneedle, the hydrogel microneedle and the glutathione reservoir are jointly applied, limitation of limited space of a microneedle body is broken through, continuous large-dose administration is realized, and the hydrogel microneedle has high percutaneous delivery efficiency.

The invention belongs to the technical field of neurobiology, and particularly relates to application of a dopamine D2 receptor G protein antagonist in preparation of a drug for treating drug addiction. Researches show that the dopamine D2 receptor G protein antagonist can inhibit recurrence after drug addiction fading induced by ignition of small-dose drugs. A mouse cocaine self-administration addiction model is adopted, a small dose of cocaine is given after model mice are subjected to regression training, and the recurrence behavior of the mouse cocaine addiction after regression is induced. A signal channel dependent on dopamine D2 receptor downstream G protein is inhibited before addiction recurrence is induced by a small dose of cocaine, and recurrence after drug-induced cocaine fading can be inhibited; however, the signal pathway for inhibiting the dependence of beta-arretin on the downstream of the dopamine D2 receptor cannot inhibit the recurrence after drug-induced cocaine fading. The invention discloses the effect of the G protein biased antagonist of the dopamine D2 receptor in treatment of drug addiction, and provides a new thought and a drug intervention target for treatment of drug addiction of cocaine and the like.

The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.

Some embodiments of the present invention include compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) of the present invention that inhibit IRAK and / or FLT3 and can be used, for example, to treat certain diseases. Some embodiments include administration and methods of using compounds of the present invention (e.g., in compositions or pharmaceutical compositions) to treat (e.g., diseases such as hematopoietic cancer, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatments using a combination of an IRAK and / or FLT3 inhibitor compound of the present invention and another therapy, such as a cancer therapy.

The present application provides a method of administration that maximizes the therapeutic effect of adrenomedullin, and a drug containing adrenomedullin provided by the method of administration. The above problem is solved by providing a drug for treating a disease, which contains adrenomedullin or a derivative thereof having adrenomedullin activity, etc. as an effective ingredient, characterized in that the disease is a disease for which a therapeutic effect is expected to be obtained by administration of adrenomedullin or a derivative thereof having adrenomedullin activity, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and the effective ingredient is administered intermittently.

The tracheal catheter comprises a catheter body, an air inflation assembly, a first drug delivery assembly and a second drug delivery assembly, an air inflation opening, a first drug delivery opening and a second drug release cavity are formed in one end of the catheter body at intervals, the air inflation assembly, the first drug delivery assembly and the second drug delivery assembly are all connected with the catheter body, one end of the air inflation assembly communicates with the air inflation opening, and the other end of the air inflation assembly communicates with the second drug release cavity. One end of the first drug delivery assembly is communicated with the first drug delivery port, and the second drug delivery assembly is communicated with the second drug release cavity. By arranging the catheter body, the inflation assembly, the first drug delivery assembly and the second drug delivery assembly, it is guaranteed that an effective artificial airway is established, and the two independent drug delivery assemblies are further arranged, so that slow and continuous drug delivery can be guaranteed to conduct anti-inflammatory or anaphylactic reactions, and according to sudden diseases or special diseases, drug delivery can be conducted through the drug delivery assemblies. The medicine is accurately administrated according to needs, timely treatment is carried out, continuous treatment and emergency supplement are both considered, and the treatment effect on local mucosal inflammation and anaphylactic reaction of a patient with long-term tracheal intubation is improved.

The invention relates to a hydrogel material capable of sequentially and controllably releasing drugs as well as a preparation method and application of the hydrogel material. The biocompatibility of the hydrogel is effectively guaranteed without an exogenous cross-linking agent, and the hydrogel has good self-repairing, viscidity and integration performance and immune regulation characteristics such as acute proinflammatory and continuous anti-inflammatory properties, and is a good biological medical dressing with practical application effect for drug delivery and treatment.

The invention belongs to the technical field of medicines, and particularly relates to a high-efficiency low-toxicity anticancer combined medicine and a pharmaceutical composition. The invention provides application of guanidine compounds combined with piperlongumine in preparation of anti-cancer drugs. Wherein the guanidine compound can be selected from metformin. Compared with a single-dose drug, the combined drug provided by the invention has better anticancer activity. Compared with platinum chemotherapeutic drugs, the drug combination scheme has the same tumor killing efficacy, and has no obvious influence on mouse weight, immune system, liver function, kidney function and the like, which indicates that the toxic and side effects of the drug combination are obviously weaker than those of the platinum chemotherapeutic drugs. Therefore, the drug combination scheme provided by the invention has a very good application prospect.

The invention relates to the technical field of injection pumps, and discloses a micro-injection pump integrating automatic bar code recognition and voice control dosing functions, the micro-injection pump comprises a shell and a voice receiving module, the voice receiving module is fixedly arranged at the top end of the shell, the shell comprises a single-layer shell, a control panel is fixedly arranged on the single-layer shell, and a voice control module is fixedly arranged on the control panel. An injection bin body is fixedly arranged at the front end of the single-layer shell, a bin door is detachably arranged on the injection bin body, when the injection bin body and the bin door are closed, the injection bin body and the bin door are in a hollow cylinder shape, and a medicine feeding push block moving left and right is arranged on the single-layer shell. And an information identification assembly, a light extrusion cylinder body positioning assembly and a split driving assembly are arranged in the injection bin body. The invention particularly provides a micro-injection pump integrating automatic bar code recognition and voice control dosing functions. The micro-injection pump is provided with an information recognition assembly, a radio module and a light extrusion cylinder body positioning assembly.

The present invention relates to the use of botulinum toxin for the preventive treatment of migraine by intramuscular injection following specific dosing and injection schemes involving injection of botulinum toxin into the frontal, temporal, occipital and cervical areas of the head and, optionally, the shoulder area. The schemes are easy to inject and provide a new treatment approach in the preventive treatment of both episodic migraine (EM) and chronic migraine (CM).

The invention concerns improvements in needle-free devices for delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

The invention provides a low-dose transdermal patch with high drug release, and relates to the technical field of transdermal patches. The low-dose transdermal patch with high drug release comprises a backing layer, an intelligent response type pressure-sensitive adhesive storage layer and an anti-sticking layer, and the intelligent response type pressure-sensitive adhesive storage layer is composed of an upper quick release adjusting layer, a middle buffer transition layer and a lower slow release core layer; the upper quick-release adjusting layer contains a temperature-sensitive penetration promoting system and is composed of composite microspheres of menthol, borneol and polyoxyethylated castor oil, the surfaces of the composite microspheres are coated with poly (N-isopropylacrylamide) temperature-sensitive coatings, when the skin temperature is higher than 34 DEG C, the coatings swell to accelerate drug release, and the content of the coatings accounts for 5%-20% (w / w) of the total weight of the upper layer. And through an intelligent response mechanism, the low-dose drug effect is improved, the stimulation is reduced, various environments are adapted, the targeting property is enhanced, and the medication safety and applicability are improved.

The invention discloses an integrated medicine adding and pressing device which comprises a cabinet body and universal wheels, the universal wheels are installed at the bottom of the cabinet body so that the cabinet body can move conveniently, the integrated medicine adding and pressing device further comprises a plurality of partition plates, a tool box and an electric control cabinet, the partition plates are fixedly installed in the cabinet body, and the cabinet body is divided into an equipment cavity, a tool box and the electric control cabinet; the tool box is used for storing tools and accessories, and electric control equipment used for controlling the pressing mechanism is installed in the electric control cabinet. The pressing mechanism is mounted in the equipment cavity of the cabinet body and is used for precisely adding chemicals, sweeping lines and removing blockage and pressing an oil pipe; and the winding drum is arranged in the equipment cavity and located on one side of the pressing mechanism, an outlet coil pipe is wound on the winding drum, and the outlet coil pipe can be connected with the water outlet end of the pressing mechanism so that oil pipe pressing or pesticide spraying can be conducted. The device can adapt to automatic and accurate chemical feeding of different wells under different conditions, and can complete partial pipeline cleaning and blockage removal and underground fault judgment through oil pipe pressing of a rod-pumped well.

The invention concerns improvements in needle-free devices for the delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free devices disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

Provided herein are pharmaceutical compositions comprising midazolam and ketamine, and methods of inducing sedation (e.g., procedural sedation) in a subject using administration of such compositions, the compositions optionally including a pharmaceutically active compound of a third class. Compositions may be in sublingual or buccal form, or incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described.

This invention provides an atomization module for an atomizer, comprising a pressure-resistant solution chamber, a pressure assembly, a heating assembly, and a sealing nozzle. The pressure assembly is connected to the pressure-resistant solution chamber and can increase the pressure inside the chamber. The sealing nozzle is connected to an outlet on the pressure-resistant solution chamber and includes a transition section and a spray plate. The spray plate has an internally closed blind hole. The transition section, the blind hole, and the outlet are interconnected. The blind hole opens from the inside out after exceeding the pressure limit, and the liquid to be atomized is sprayed out from the blind hole. The inner diameters of the pressure-resistant solution chamber, the transition section, and the blind hole decrease sequentially. The heating assembly can heat the pressure-resistant solution chamber. The atomization module of this invention has a faster atomization rate, a larger capacity range for atomized solution per spray, and no special requirements on the device posture during atomization. It can deliver both micro-dose and large-dose drugs as needed, making it more widely applicable.

The invention discloses a sitagliptin phosphate pharmaceutical composition as well as a preparation, a preparation method and application thereof. The pharmaceutical composition comprises sitagliptin phosphate, HP-beta-CD and mesoporous silica. According to the invention, a synergistic effect is generated by utilizing a molecular-level clathration effect of HP-beta-CD and a nano-level confinement adsorption effect of mesoporous silica, so that chemical degradation of sitagliptin phosphate, especially generation of a genotoxic impurity NTTP, is remarkably inhibited from molecular and physical double levels, and the stability of a product is greatly improved. Meanwhile, the mesoporous silica effectively solves the technical problems that HP-beta-CD is strong in hygroscopicity and not easy to directly tablet, and the content uniformity of low-dose drugs is fundamentally ensured by forming uniform composite particles. The process is simple, granulation is not needed, the tablet is suitable for industrial production, the prepared tablet is excellent in stability and high in safety, and animal experiments show that the bioavailability of the tablet is superior to that of a commercially available reference preparation.